MedPage Today January 20, 2025
Kristen Monaco

— VA researchers found lower risks for 42 diverse outcomes and increased risks for 19 others

An observational study of 175 health outcomes using Veterans Affairs (VA) data for nearly 2 million individuals uncovered new insights about possible risks and benefits of GLP-1 receptor agonists.

Over a median of 3.68 years, adults with type 2 diabetes who added a GLP-1 agent to their treatment plan had significantly decreased risks for 42 diverse outcomes, increased risks for 19 outcomes, and no association with 114 outcomes compared with usual care, reported Ziyad Al-Aly, MD, of Washington University in St. Louis, and colleagues.

“The results may be useful for informing clinical care, enhancing pharmacovigilance, and guiding the development of mechanistic and clinical research...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Clinical Trials, Patient / Consumer, Pharma / Biotech, Provider, Trends
Related Articles:
Once high-flying Bluebird Bio sells itself to private equity after tough times for the gene therapy maker
Stakeholder Management and Interoperability of Biosimilars
Anne Wojcicki has a new offer to take 23andMe private, this time for $74.7 million
Pharma Pulse 2/21/25: RWE in Medical Research and Drug Development, Inhaled Antibody Therapy for RSV & more
FDA approves first rapid-acting insulin biosimilar for diabetes

Share This Article